Fluid therapy in acute pancreatitis comparing balanced solutions and normal saline: A systematic review, meta-analysis and trial sequential analysis.

IF 3.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Lin Gao, Hsiang-Wei Wang, Zi-Rui Liu, Yi-Zhen Xu, Lu Ke, Wei-Qin Li, John A Windsor
{"title":"Fluid therapy in acute pancreatitis comparing balanced solutions and normal saline: A systematic review, meta-analysis and trial sequential analysis.","authors":"Lin Gao, Hsiang-Wei Wang, Zi-Rui Liu, Yi-Zhen Xu, Lu Ke, Wei-Qin Li, John A Windsor","doi":"10.1016/j.hbpd.2025.04.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Isotonic crystalloids are recommended as the first choice for fluid therapy in acute pancreatitis (AP), with normal saline (NS) and lactate Ringer's (LR) used most often. Evidence based recommendations on the type of fluid are conflicting and generally come from small single-center randomized controlled trials (RCTs). We therefore conducted a systematic review and meta-analysis to compare the effect of balanced solutions (BS) versus NS on patient-centered clinical outcomes in AP.</p><p><strong>Methods: </strong>From four databases searched up to October 2024, we included only RCTs of adult patients with AP that compared the use of BS (including LR, acetate Ringer's, etc.) with NS. The primary outcome was the disease advances from AP to moderately severe and severe AP (MSAP/SAP). Trial sequential analyses (TSA) were conducted to control for type-I and type-II errors and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the quality of evidence.</p><p><strong>Results: </strong>Six RCTs were identified and included, involving 260 patients treated with BS and 298 patients with NS. Patients who received the BS had less MSAP/SAP [odds ratio (OR) = 0.50, 95 % confidence interval (CI): 0.29 to 0.85, P = 0.01, I<sup>2</sup> = 0 %; 5 studies, 299 patients], reduced need of ICU admission (OR = 0.60, 95 % CI: 0.39 to 0.93, P = 0.02, I<sup>2</sup> = 0 %; 5 studies, 507 patients) and shorter length of hospital stay [mean difference (MD) = -0.88, 95 % CI:1.48 to -0.28, P = 0.004, I<sup>2</sup> = 0 %; 6 studies, 558 patients; confirmed by TSA with high certainty] compared with those who received NS. The evidence for most of the clinical outcomes was rated as moderate to low due to the risk of bias, imprecision and inconsistency.</p><p><strong>Conclusions: </strong>BS, compared with NS, was associated with improved clinical outcomes in patients with AP. However, given the moderate to low quality of evidence for most of the outcomes assessed, further trials are warranted.</p>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatobiliary & Pancreatic Diseases International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hbpd.2025.04.002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Isotonic crystalloids are recommended as the first choice for fluid therapy in acute pancreatitis (AP), with normal saline (NS) and lactate Ringer's (LR) used most often. Evidence based recommendations on the type of fluid are conflicting and generally come from small single-center randomized controlled trials (RCTs). We therefore conducted a systematic review and meta-analysis to compare the effect of balanced solutions (BS) versus NS on patient-centered clinical outcomes in AP.

Methods: From four databases searched up to October 2024, we included only RCTs of adult patients with AP that compared the use of BS (including LR, acetate Ringer's, etc.) with NS. The primary outcome was the disease advances from AP to moderately severe and severe AP (MSAP/SAP). Trial sequential analyses (TSA) were conducted to control for type-I and type-II errors and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the quality of evidence.

Results: Six RCTs were identified and included, involving 260 patients treated with BS and 298 patients with NS. Patients who received the BS had less MSAP/SAP [odds ratio (OR) = 0.50, 95 % confidence interval (CI): 0.29 to 0.85, P = 0.01, I2 = 0 %; 5 studies, 299 patients], reduced need of ICU admission (OR = 0.60, 95 % CI: 0.39 to 0.93, P = 0.02, I2 = 0 %; 5 studies, 507 patients) and shorter length of hospital stay [mean difference (MD) = -0.88, 95 % CI:1.48 to -0.28, P = 0.004, I2 = 0 %; 6 studies, 558 patients; confirmed by TSA with high certainty] compared with those who received NS. The evidence for most of the clinical outcomes was rated as moderate to low due to the risk of bias, imprecision and inconsistency.

Conclusions: BS, compared with NS, was associated with improved clinical outcomes in patients with AP. However, given the moderate to low quality of evidence for most of the outcomes assessed, further trials are warranted.

比较平衡溶液和生理盐水对急性胰腺炎的液体治疗:一项系统回顾、荟萃分析和试验序列分析。
背景:等渗晶体液被推荐为急性胰腺炎(AP)液体治疗的首选,其中最常用的是生理盐水(NS)和乳酸林格液(LR)。基于证据的液体类型建议是相互矛盾的,通常来自小型单中心随机对照试验(rct)。因此,我们进行了系统回顾和荟萃分析,比较平衡溶液(BS)和NS对AP患者中心临床结果的影响。方法:从四个数据库检索到2024年10月,我们只纳入了成年AP患者的rct,比较BS(包括LR,醋酸林格等)与NS的使用。主要转归是AP进展为中重度和重度AP (MSAP/SAP)。采用试验序贯分析(TSA)来控制i型和ii型错误,采用分级推荐评估、发展和评价(GRADE)来评估证据质量。结果:确定并纳入6项随机对照试验,涉及260例BS患者和298例NS患者。接受BS的患者MSAP/SAP较低[比值比(OR) = 0.50, 95 %置信区间(CI): 0.29 ~ 0.85, P = 0.01, I2 = 0 %;5项研究,299例患者],减少了ICU住院需求(OR = 0.60, 95 % CI: 0.39 ~ 0.93, P = 0.02, I2 = 0 %;5项研究,507例患者)和更短的住院时间[平均差异(MD) = -0.88, 95 % CI:1.48 ~ -0.28, P = 0.004, I2 = 0 %;6项研究,558例患者;与接受NS治疗的患者相比。由于存在偏倚、不精确和不一致的风险,大多数临床结果的证据被评为中等至低。结论:与NS相比,BS与AP患者的临床结果改善相关。然而,鉴于大多数评估结果的证据质量为中等至低,进一步的试验是有必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.40
自引率
6.10%
发文量
152
审稿时长
3.0 months
期刊介绍: Hepatobiliary & Pancreatic Diseases International (HBPD INT) (ISSN 1499-3872 / CN 33-1391/R) a bimonthly journal published by First Affiliated Hospital, Zhejiang University School of Medicine, China. It publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatobiliary and pancreatic diseases. Papers cover the medical, surgical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas under the headings Liver, Biliary, Pancreas, Transplantation, Research, Special Reports, Editorials, Review Articles, Brief Communications, Clinical Summary, Clinical Images and Case Reports. It also deals with the basic sciences and experimental work. The journal is abstracted and indexed in SCI-E, IM/MEDLINE, EMBASE/EM, CA, Scopus, ScienceDirect, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信